PATENT CLAIM ANALYSIS

Application Number: 15888634
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["424", "001650"]

Abstract:
The present invention provides bivalent and multivalent ligands with a view to improving the affinity and pharmacokinetic properties of a urea class of PSMA inhibitors. The compounds and their synthesis can be generalized to multivalent compounds of other target antigens. Because they present multiple copies of the pharmacophore, multivalent ligands can bind to receptors with high avidity and affinity, thereby serving as powerful inhibitors. The modular multivalent scaffolds of the present invention, in one or more embodiments, contains a lysine-based (α-, ε-) dialkyne residue for incorporating two or more antigen binding moieties, such as PSMA binding Lys-Glu urea moieties, exploiting click chemistry and one or more additional lysine residues for subsequent modification with an imaging and/or therapeutic nuclides or a cytotoxic ligands for tumor cell killing.

Claim (Index 7):
A pharmaceutical composition comprising a compound, salt, solvate, or stereoisomer of  claim 1 , and a pharmaceutically acceptable carrier.

Metadata:
- Claim Count in Document: 45.0
- Percentile: 88.0
- Lexical Diversity: 1.61628
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14362011', '14385090', '14116423', '14847593', '14352096']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7175746217739573
- 35 USC 102 Novelty (BERT): 0.564629151679066
- Combined Prediction Score: 0.7022800747644681
- Mean Citation Score: 349.160212
- Max Citation Score: 422.76047
- Similarity Product: 417.55516801134826

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test